• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report.2014年至2017年塞尔维亚结直肠癌服务的医疗成本：国家数据报告。
Front Pharmacol. 2019 May 15;10:526. doi: 10.3389/fphar.2019.00526. eCollection 2019.
2
Medical cost of breast cancer services in Serbia between 2010 and 2019: national data report.2010年至2019年塞尔维亚乳腺癌服务的医疗成本：国家数据报告。
Front Public Health. 2024 Mar 28;12:1378886. doi: 10.3389/fpubh.2024.1378886. eCollection 2024.
3
Colorectal cancer mortality trends in Serbia during 1991-2010: an age-period-cohort analysis and a joinpoint regression analysis.1991 - 2010年塞尔维亚结直肠癌死亡率趋势：年龄 - 时期 - 队列分析和连接点回归分析
Chin J Cancer. 2016 Jun 22;35(1):55. doi: 10.1186/s40880-016-0118-y.
4
Organized colorectal cancer screening in Serbia - the first round within 2013-2014.塞尔维亚有组织的结直肠癌筛查——2013 - 2014年第一轮筛查
Vojnosanit Pregl. 2016 Apr;73(4):360-7. doi: 10.2298/VSP150421113B.
5
Radiation therapy remains the key cost driver of oncology inpatient treatment.放射治疗仍然是肿瘤住院治疗的主要成本驱动因素。
J Med Econ. 2015 Jan;18(1):29-36. doi: 10.3111/13696998.2014.971162. Epub 2014 Oct 10.
6
[Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia].[塞尔维亚共和国2型糖尿病治疗费用评估]
Vojnosanit Pregl. 2009 Apr;66(4):271-6. doi: 10.2298/vsp0904271b.
7
Reimbursement of targeted cancer therapies within 3 different European health care systems.3种不同欧洲医疗保健系统中靶向癌症疗法的报销情况。
Clin Ther. 2015 Feb 1;37(2):474-80. doi: 10.1016/j.clinthera.2014.12.005. Epub 2015 Jan 28.
8
[Assessment of required resources for implementation of national breast cancer screening program in Serbia].[塞尔维亚国家乳腺癌筛查项目实施所需资源评估]
Srp Arh Celok Lek. 2014 Jan-Feb;142(1-2):59-66. doi: 10.2298/sarh1402059m.
9
[Analysis of mortality in cancer of the large intestine in a cohort group in Serbia from 1971 to 1996].[1971年至1996年塞尔维亚队列组中大肠癌死亡率分析]
Srp Arh Celok Lek. 2002 May-Jun;130(5-6):173-7. doi: 10.2298/sarh0206173g.
10
Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols.转移性结直肠癌的五年生存率及治疗费用：传统治疗方案与基于单克隆抗体的治疗方案对比
Expert Rev Anticancer Ther. 2015;15(8):963-70. doi: 10.1586/14737140.2015.1059280. Epub 2015 Jun 18.

引用本文的文献

1
Medical treatment cost for Chinese inpatients with colorectal cancer by sites.中国结直肠癌住院患者按发病部位划分的医疗费用。
Front Public Health. 2025 Jun 11;13:1605887. doi: 10.3389/fpubh.2025.1605887. eCollection 2025.
2
Two Decades of Progress in Personalized Medicine of Colorectal Cancer in Serbia-Insights from the Institute for Oncology and Radiology of Serbia.塞尔维亚结直肠癌个性化医疗二十年进展——来自塞尔维亚肿瘤与放射学研究所的见解
Biomedicines. 2024 Oct 8;12(10):2278. doi: 10.3390/biomedicines12102278.
3
Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.保加利亚罕见癌症孤儿药的可及性与获取情况：延误及公共支出分析
Cancers (Basel). 2024 Apr 12;16(8):1489. doi: 10.3390/cancers16081489.
4
Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020.低收入和中等收入国家转移性结直肠癌（mCRC）治疗的资源导向型决策：埃及医学科学基金会（EFMS）2020年共识建议
Cancer Manag Res. 2022 Feb 28;14:821-842. doi: 10.2147/CMAR.S340030. eCollection 2022.
5
A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries.部分巴尔干国家结直肠癌统计数据与经济指标的相关性研究
Front Public Health. 2020 Feb 18;8:29. doi: 10.3389/fpubh.2020.00029. eCollection 2020.

本文引用的文献

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.欧洲癌症发病率和死亡率模式：2018 年 40 个国家和 25 种主要癌症的估计值。
Eur J Cancer. 2018 Nov;103:356-387. doi: 10.1016/j.ejca.2018.07.005. Epub 2018 Aug 9.
3
Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe-A Retrospective Analysis from Serbia.东南欧放射学服务成本与使用模式估计——来自塞尔维亚的回顾性分析
Value Health Reg Issues. 2013 Sep-Oct;2(2):218-225. doi: 10.1016/j.vhri.2013.07.002. Epub 2013 Sep 13.
4
Pricing of monoclonal antibody therapies: higher if used for cancer?单克隆抗体疗法的定价：用于癌症时是否更高？
Am J Manag Care. 2018 Feb;24(2):109-112.
5
Colorectal cancer-global burden, trends, and geographical variations.结直肠癌——全球负担、趋势及地理差异
J Surg Oncol. 2017 Apr;115(5):619-630. doi: 10.1002/jso.24578. Epub 2017 Feb 13.
6
Worldwide burden of colorectal cancer: a review.全球结直肠癌负担：综述
Updates Surg. 2016 Mar;68(1):7-11. doi: 10.1007/s13304-016-0359-y. Epub 2016 Apr 11.
7
Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols.转移性结直肠癌的五年生存率及治疗费用：传统治疗方案与基于单克隆抗体的治疗方案对比
Expert Rev Anticancer Ther. 2015;15(8):963-70. doi: 10.1586/14737140.2015.1059280. Epub 2015 Jun 18.
8
End-of-life costs of medical care for advanced stage cancer patients.晚期癌症患者临终医疗费用。
Vojnosanit Pregl. 2015 Apr;72(4):334-41. doi: 10.2298/vsp1504334k.
9
Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma.基于单克隆抗体的乳腺癌、结直肠癌和非霍奇金淋巴瘤一线肿瘤治疗方案的成本差异。
J BUON. 2014 Oct-Dec;19(4):1111-20.
10
Economic burden of cancer across the European Union: a population-based cost analysis.欧盟癌症的经济负担：基于人群的成本分析。
Lancet Oncol. 2013 Nov;14(12):1165-74. doi: 10.1016/S1470-2045(13)70442-X. Epub 2013 Oct 14.

Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report.

作者信息

Vekic Berislav, Dragojevic-Simic Viktorija, Jakovljevic Mihajlo, Pilipovic Filip, Simic Radoje, Zivic Rastko, Radovanovic Dragce, Rancic Nemanja

机构信息

Department of Surgery, Clinical Centre "Dr. Dragisa Misovic", Belgrade, Serbia.

Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.

出版信息

Front Pharmacol. 2019 May 15;10:526. doi: 10.3389/fphar.2019.00526. eCollection 2019.

DOI:10.3389/fphar.2019.00526
PMID:31156439
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6530405/
Abstract
摘要